secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086344
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q2 net loss $78M including $63.8M goodwill impairment; FY24 guidance cut to $225-235M
--------------------------------------------------------------------------------

- Revenue $57.6M (+1% YoY, +5.5% sequentially); Life Sciences Services up 8%, Products down 10%.
- GAAP EPS loss $1.62 (diluted); Adjusted EBITDA negative $3.8M vs. negative $1.3M a year ago.
- Recorded $63.8M impairment charge related to MVE Biological Solutions goodwill write-off.
- FY 2024 revenue guidance revised to $225-235M from prior range; expects positive adjusted EBITDA in 2025.
- Announced $200M stock/note repurchase program; repurchased $160M of 2026 convertible notes for $141.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465924086344/0001104659-24-086344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465924086344/tm2421008d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer